Testing a new solution to improve DCD kidney transplants
Part of Heart & circulation clinical trials.
This trial tests a special solution (iCM012) that is used to wash and preserve kidneys from older deceased donors (ages 55–75) before they are transplanted. The goal is to see if it helps the kidneys work better after transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have been on dialysis for more than 12 months.
- This is your first kidney transplant.
- Your blood type must match the donor's, and special tests must show your body is unlikely to reject the kidney.
- You must be able to take certain anti-rejection medicines (thymoglobulin and tacrolimus or cyclosporine).
- You cannot be pregnant or nursing, and if you could become pregnant, you must use reliable birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a machine method that keeps a donated kidney working “outside the body” so it may be better repaired before transplant. It is designed for certain first/second kidney transplants using specific donor types and storage methods.
This trial tests whether giving a special type of immune cells from your kidney donor (called ECP-DL cells) can help your body accept the new kidney without strong anti-rejection drugs. It is for people who are getting their first kidney transplant from a donor who is not a perfect genetic match.
This study checks if pumping a special fluid through donor kidneys (machine perfusion) helps predict how well the kidney will work after transplant. It's for people getting a kidney from an older donor or one with some health issues.
This Phase 2 trial studies a treatment using immune cells made from your living donor, given around the time of kidney transplant. It aims to improve transplant safety and outcomes by adjusting the immune response to the new kidney.
This trial tests a new medicine called imlifidase that quickly removes harmful antibodies from the blood. It is given to children before a kidney transplant to make the donated kidney more likely to be accepted, especially when standard desensitisation methods have failed.
This study tests an experimental drug called CID-103 to treat antibody-mediated rejection (ABMR), a type of immune response that damages transplanted kidneys. The drug targets immune cells that attack the transplant, and researchers hope it may help preserve kidney function and prevent transplant failure.
Hear when a new Ischemia Reperfusion Injury trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.